DXR

DAXOR CORP 10-Q Summary: Period Ended June 30, 2004

Business Context and Reporting Period

This Form 10-Q covers the quarterly and six-month periods ended June 30, 2004. DAXOR Corporation operates in two primary segments: the development and marketing of the BVA-100 Blood Volume Analyzer and associated kits, and the provision of localized semen and blood banking services. The company maintains a significant investment portfolio, primarily consisting of utility stocks, which serves as a major revenue source.

Key Financial Metrics

Note: Operating cash flow for the six months ended June 30, 2004, was a net use of $(754,665).

Material Changes vs. Prior Period

• Revenue Growth: Total revenues increased 37% year-over-year for the six-month period, driven primarily by a significant increase in realized capital gains on securities ($426,696 in 2004 vs. $81,263 in 2003) and higher dividend income.
• Operating Performance: Operating revenues from core business activities (laboratories and product sales) increased 30% to $662,983 for the six months, though they declined 12% in the most recent quarter compared to the prior year quarter.
• Expense Increases: Selling, General, and Administrative (SG&A) expenses rose to $1,537,378 for the six months (up from $1,295,354 in 2003) due to the hiring of additional sales and marketing personnel to support the BVA-100 expansion.
• Debt Levels: Loans payable increased by approximately $1.54 million to $4.04 million, reflecting increased margin debt and bank loans secured by the company's marketable securities.
• Profitability: The net loss narrowed significantly to $(241,697) from $(522,239) in the prior year period, largely due to investment gains offsetting operating losses.

Guidance, Outlook, and Risks

Outlook and Strategy: Management anticipates that sales of the BVA-100 Blood Volume Analyzer and kits will remain the major source of future income. The company plans to expand its sales force and support services, aiming to establish blood volume measurement as a standard of care. A new financing arrangement with Daxor Capital (via De Lage Landen) allows for equipment leasing without immediate capital outlay.

Risks and Contingencies:

• Market Risk: The company's financial position is heavily correlated with the electric utility industry, as 90-95% of its investment portfolio consists of utility stocks. Fluctuations in this sector directly impact total assets and revenue.
• Liquidity: While the company holds significant assets in securities, cash on hand is low ($20,028). Current liabilities include $8.7 million in deferred taxes that would only be realized if the entire portfolio were sold.
• Legal: Two pending claims are noted, but management believes they lack merit and will not materially affect financial statements.

Key Facts for Investor Verification

• Revenue Composition: Verify the sustainability of revenue, as investment income (dividends and capital gains) significantly exceeded operating revenues ($1.39M vs. $0.66M) for the six-month period.
• Debt Security: Confirm that the $4.04 million in loans payable is fully secured by the $48.5 million investment portfolio and review margin call risks.
• Deferred Tax Liability: Note that $8.7 million of current liabilities represents deferred taxes on unrealized gains; these are not immediate cash obligations unless the portfolio is liquidated.
• Operating Cash Flow: Investigate the negative operating cash flow of $(754,665) and the company's reliance on investment activities and financing to maintain liquidity.
• Product Adoption: Monitor the progress of the BVA-100 marketing expansion and the impact of anticipated peer-reviewed publications on sales velocity.